Islet amyloid polypeptide (amylin) does not seem to be directly involved in the development of gestational diabetes mellitus

Gynecologic and Obstetric Investigation

Volumn 44, Issue 1, 1997, Pages 6-10

  Grigorakis, Stelios I ^a   Alevizaki, Maria ^a   Rapti, Eva ^a   Anastasiou, Eleni ^a   Alevizaki, Calliope C ^a   Souvatzoglou, Athanassios ^a  

^a ALEXANDRA HOSPITAL   (Greece)

Author keywords

Amylin; Gestational diabetes mellitus; Islet amyloid polypeptide; Oral glucose tolerance test; Placenta

Indexed keywords

AMYLIN; C PEPTIDE; GLUCOSE; INSULIN; RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTHERN BLOTTING; ORAL GLUCOSE TOLERANCE TEST; PLACENTA; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0030800086     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000291400     Document Type: Article

References (34)

1. Jovanovic-Peterson L, Peterson CM: Pregnancy in the diabetic woman. Endocrinol Mctab Clinic North Am 1992;21:433-456.
2. Kuhl C: Insulin secretion and insulin resistance in pregnancy and GDM. Implications for diagnosis and management. Diabetes 1991:40 (suppl 2): 18-24.
3. Polonsky KS, Sturis J, Bell GI: Non-insulin-dependent diabetes mellitus: A genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996,334: 777-783.
4. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E. Brunnbauer M. Woloszc-zuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its cosecretion with insulin in humans. Diabctologia 1991;34:52-54.
5. Ohsawa H. Kanatsuka A, Yamaguchi T, Maki-no H, Yoshida S: Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochcm Biophys Res Commun 1989:160:961-967.
6. Leighton B, Cooper GJS: Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988;335:632-635.
7. Permert J, Larsson J, Wcstcrmark GT. Herrington MK, Christmanson L. Pour PM. Wes-termark P. Adrian TE: Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994;330:313-318.
8. Gaeta LSL, Rink TJ: Amylin: A new hormone as a therapeutic target in diabetes mellitus and other metabolic diseases. Med Chem Res 1994: 3:483-490.
9. Wcstcrmark P. Johnson KH, O'Brien TD, Bet-sholtz C: Islet amyloid polypeptide: A novel controversy in diabetes research. Diabctologia 1992;35:297-303.
10. Bretherton-Watt D, Gilbey SG, Ghatci MA, Beacham J, Macrae AD. Bloom SR: Very high concentrations of islet amyloid polypeptide are necessary' to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 1992;74:1032-1035.
11. Wilding JPH, Khandan-Nia N, Bennet WM. Gilbey SG. Beacham J, Ghatei MA, Bloom SR: Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic cuglycaemic clamp in humans. Diabctologia 1994;37:166-169.
12. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994;368:756-760.
13. Chen CC-L, Chang C-C, Krieger DT. Bardin CW: Expression and regulation of pro-opiome-lanocortm-likc gene in the ovary and placenta: Comparison with the testis. Endocrinology 1986:118:2382-2389.
14. Grino M, Chrousos GP, Margioris AN: The corticotrophin releasing hormone gene is expressed in human placenta. Biochem Biophys ResCommun 1987;148:1208-1214.
15. Alevizaki M, Shiraishi A, Rassool FV, Ferrier GJM, MacIntyre 1, Legon S: The calcitoninlike sequence of the beta CGRP gene. FEBS Lett 1986;206:47-51.
16. Girgis SI, Alevizaki M. Denny P. Ferrier GJM. Legon S: Generation of probes for peptides with highly degenerate codons using mixed primer PCR. Nucleic Acids Res 1988:16: 10371.
17. Alevizaki M. Dai K. Grigorakis SI, Legon S, Souvatzoglou A: Amylin/islct amyloid polypeptide expression in medullary carcinoma of the thyroid: Correlation with the expression of the related calcitonin/CGRP genes. Clin Endocrinol 10x0 1994;41:21-26.
18. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057.
19. Ludvik B, Lell B, Hartter E. Schnack C. Prager R: Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 1991;40:1615-1619.
20. Ferrier GJM, Pierson AM, Jones PM, Bloom SR, Girgis SI, Legon S: Expression of the rat amylin (IAPP/DAP) gene. J Mol Endocrinol 1989:3:R1-R4.
21. Mossclman S, Hoppcncr JWM, Lips CJM. Jansz HS: The complete islet amyloid polypeptide precursor is encoded by two exons. FEBS Lett 1989;247:154-158.
22. Zweers EJK, Bravcnboer B. van Hulst KL, Lips CJM. Christiaens GCML, Hackeng WHL, Er-kclens DW: Glucose stimulated islet amyloid polypeptide and gestational diabetes mellitus. Diabctologia 1992;35(suppl 1):A 179.
23. Alam T, Chen L. Ogawa A. Leffert JD. Unger RH. Luskey KL: Coordinate regulation of amylin and insulin expression in response to hypoglycemia and fasting. Diabetes 1992:41:508-514.
24. Ludvik B, Clodi M, Kautzky-Willcr A, Capck M, Hartter E. Pacini G, Prager R: Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabctologia 1993;36:84-87.
25. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B. Strcli C, Waldhausl W. Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabeto-logia 1994;37:188-194.
26. Burt RL. Davidson IWF: Insulin half-life and utilisation in normal pregnancy. Obstet Gynecol 1974:43:161-70.
27. Ferrannini E, Cobelli C: The kinetics of insulin in man. Diabetes Metab Rev 1987;3:335-397.
28. Ludvik B, Bcrzlanovich A, Hartter E, Lell B, Prager H, Graf H: Increased amylin levels in patients on chronic hemodialysis (abstract). Nephrol Dial Transplant 1990;8:694-695A.
29. Blackard WG. Clore JN, Kcllum JM: Amylinz Insulin secretory ratios in morbidly obese man: Inverse relationship with glucose disappearance rate. J Clin Endocrinol Metab 1994;78: 1257-1260.
30. Stridsberg M. Sandler S, Wilander E: Cosecretion of islet amyloid polypeptide (IAPP) and insulin from isolated rat pancreatic islets following stimulation or inhibition of β-cell function. Regul Pept 1993;45:363-370.
31. Bennet WM. Beis CS. Ghatei MA. Byfield PGH. Bloom SR: Amylin tonally regulates arginine-stimulated insulin secretion in rats. Dia-betologia 1994;37:436-438.
32. Mulder H, Ahren B, Stridsberg M, Sundler F: Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Dia-betologia 1995;38:395-402.
33. Ogawa A. Harris V, McCorkle SK. Unger RH. Luskey KL: Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 1990;85:973-976.
34. Sanke T. Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M, Nanjo K: Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabeto-logia 1991;34:129-132.